Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (622)	5/18/1998 11:41:00 PM
From: RealMuLan	Read Replies (1) \| Respond to of 900

From Yahoo LIPO thread. Montgomery rate it BUY. Message 358 of 365 Reply Montgomery Securities - 12:10pm PDT 18-May-98 sbinsanjose (49 creeping up on 50/M/San Jose, CA) May 18 1998 8:25PM EDT Following scanned from a fax and manually corrected.....I think I got all the OCR errors corrected.....I don't know how this is going to layout in the post, but thought it might be of interest to someone...Do your own research....just posting what I see.... ============================================================== 12:10pm PDT 18-May-98 Montgomery Securities (D. Crossen 415 627-2955) LIPO LIPO: Herceptin Data in Breast cancer a Major Boost for Liposome's D-99 NATIONSBANC MONTGOMERY**NATIONSBANC MONTGOMERY**NATIONSBANC MONTGOMERY THE LIPOSOME COMPANY, INC. RATING: BUY May 18, 1998 BIOTECHNOLOGY NASDAQ: LIPO David K. Crossen (415} 627-2055 First Call Tom E. Hancock (415) 627-2487 DJIA; 9089 S&P 500:1108 Price: $7-7/8 FY Ends 12/31 1996 1997A 1998E 52-Week Range: $28-4 Fully Diluted Share O/S: 39 MM Q1 (Mar) ($0.16) ($0.12) ($0.13) Market Capitalization: $295.6 MM 02 [Jun] (0 17) C0.23) (0.14) Avg. Daily Vol. (3 mos.); 257,983 Q3 (Sep) (0.16) (0.17) (0.12) Secular EPS Growth N/M 04 (Dec) {0.09) (0.191 (9.10) 1998E Revenues: $66.8 MM Fiscal Year {$0.57) ($0.71) ($0.49) Market Cap./Revenues: 4.4x P/E W/M N/M N/M 12/97 Total Debt: N/M P/E/S N/M N/M N/M 12/97 LTD/Total Cap.: N/M 12/97 ROAE: N/M 12/97 Shareholders' Eq.: $73.7 MM 12/97 book Value/Share: $1.96 Dividend/Yield: None ú NationsBanc Montgomery Securities LLC currently maintains a market in this security. HERCEPTIN DATA IN BREAST CANCER A MAJOR BOOST FOR L!IPOSOME'S D-99 Data presented over the weekend on Genentech's Herceptin {an antibody directed at the HER-2 receptor) provides some encouragement for patients with breast cancer. However, the data could provide a major boost for Liposome's D-99, a liposomal version of doxorubicin, and for Sequus's Doxil. Only 30% of breast cancer patients express the HER-2 receptor and would be candidates for treatment. However, in appropriate patients the combination of Herceptin and chemotherapy increased the response rate for patients to 49% from 32%, with the duration of response increased by 57% and overall remission increased by 65%. In particular, Herceptin, plus showed a 52% response rate vs. 43% for doxorubicin alone, and Herceptin plus Taxol showed a 42% response rate vs. 16% for Taxol alone. The problem with the Herceptin/doxorubicin combination, is a significant increase in cardiotoxicity vs. doxorubincin alone (over 16% vs. 2% for doxorubicin alone). The availability of Herceptin, which we believe will be widely used, virtually mandates that a Liposomal version of doxorubicin with a lower risk of cardiotoxicity will be used. We expect that D-99 will be approved by year-end 1998 and launched in early 1999 by The Liposome Company. We believe the price for six cycles will be in the range of $6,000 vs. $16,000 for Sequus's Doxil. We believe D-99 has the potential for sales in excess, of $200 million. We maintain our BUY on The Liposome Company. The Liposome Company develops encapsulated liposome based drugs for %he treatment of serious fungal infections and other diseases. The company currently markets Abelcet, & liposomal therapy for the treatment of systemic fungal infections. D-99 is also in development for breast cancer. First Call Corporation - all rights reserved. 617/345-2500